Your browser doesn't support javascript.
loading
The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells.
Wenzel, Jan; Lampe, Josephine; Müller-Fielitz, Helge; Schuster, Raphael; Zille, Marietta; Müller, Kristin; Krohn, Markus; Körbelin, Jakob; Zhang, Linlin; Özorhan, Ümit; Neve, Vanessa; Wagner, Julian U G; Bojkova, Denisa; Shumliakivska, Mariana; Jiang, Yun; Fähnrich, Anke; Ott, Fabian; Sencio, Valentin; Robil, Cyril; Pfefferle, Susanne; Sauve, Florent; Coêlho, Caio Fernando Ferreira; Franz, Jonas; Spiecker, Frauke; Lembrich, Beate; Binder, Sonja; Feller, Nina; König, Peter; Busch, Hauke; Collin, Ludovic; Villaseñor, Roberto; Jöhren, Olaf; Altmeppen, Hermann C; Pasparakis, Manolis; Dimmeler, Stefanie; Cinatl, Jindrich; Püschel, Klaus; Zelic, Matija; Ofengeim, Dimitry; Stadelmann, Christine; Trottein, François; Nogueiras, Ruben; Hilgenfeld, Rolf; Glatzel, Markus; Prevot, Vincent; Schwaninger, Markus.
Afiliação
  • Wenzel J; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Lampe J; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Müller-Fielitz H; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Schuster R; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Zille M; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Müller K; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Krohn M; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Körbelin J; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Zhang L; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Özorhan Ü; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Neve V; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Wagner JUG; Department of Oncology, Hematology & Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bojkova D; Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.
  • Shumliakivska M; German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.
  • Jiang Y; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Fähnrich A; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Ott F; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Sencio V; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Robil C; Institute for Cardiovascular Regeneration, Cardiopulmonary Institute (CPI), University Frankfurt, Frankfurt, Germany.
  • Pfefferle S; Institute of Medical Virology, University Frankfurt, Frankfurt, Germany.
  • Sauve F; Institute for Cardiovascular Regeneration, Cardiopulmonary Institute (CPI), University Frankfurt, Frankfurt, Germany.
  • Coêlho CFF; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Franz J; Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
  • Spiecker F; Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.
  • Lembrich B; Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
  • Binder S; Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.
  • Feller N; Centre d'Infection et d'Immunité de Lille, Inserm U1019, CNRS UMR 9017, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.
  • König P; Centre d'Infection et d'Immunité de Lille, Inserm U1019, CNRS UMR 9017, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.
  • Busch H; Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Collin L; Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, DISTALZ, EGID, Lille, France.
  • Villaseñor R; Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, DISTALZ, EGID, Lille, France.
  • Jöhren O; Institute of Neuropathology, University Medical Center, Göttingen, Germany.
  • Altmeppen HC; Campus Institute for Dynamics of Biological Networks, University of Göttingen, Göttingen, Germany.
  • Pasparakis M; Max Planck Institute for Experimental Medicine, Göttingen, Germany.
  • Dimmeler S; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Cinatl J; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Püschel K; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Zelic M; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
  • Ofengeim D; DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel and Frankfurt, Germany.
  • Stadelmann C; Airway Research Center North, Member of the German Center for Lung Research (DZL), Lübeck, Germany.
  • Trottein F; Institute of Anatomy, University of Lübeck, Lübeck, Germany.
  • Nogueiras R; Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
  • Hilgenfeld R; Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.
  • Glatzel M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.
  • Prevot V; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.
  • Schwaninger M; Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
Nat Neurosci ; 24(11): 1522-1533, 2021 11.
Article em En | MEDLINE | ID: mdl-34675436
Coronavirus disease 2019 (COVID-19) can damage cerebral small vessels and cause neurological symptoms. Here we describe structural changes in cerebral small vessels of patients with COVID-19 and elucidate potential mechanisms underlying the vascular pathology. In brains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals and animal models, we found an increased number of empty basement membrane tubes, so-called string vessels representing remnants of lost capillaries. We obtained evidence that brain endothelial cells are infected and that the main protease of SARS-CoV-2 (Mpro) cleaves NEMO, the essential modulator of nuclear factor-κB. By ablating NEMO, Mpro induces the death of human brain endothelial cells and the occurrence of string vessels in mice. Deletion of receptor-interacting protein kinase (RIPK) 3, a mediator of regulated cell death, blocks the vessel rarefaction and disruption of the blood-brain barrier due to NEMO ablation. Importantly, a pharmacological inhibitor of RIPK signaling prevented the Mpro-induced microvascular pathology. Our data suggest RIPK as a potential therapeutic target to treat the neuropathology of COVID-19.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Barreira Hematoencefálica / Peptídeos e Proteínas de Sinalização Intracelular / Microvasos / Proteases 3C de Coronavírus / SARS-CoV-2 Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Neurosci Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Barreira Hematoencefálica / Peptídeos e Proteínas de Sinalização Intracelular / Microvasos / Proteases 3C de Coronavírus / SARS-CoV-2 Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Neurosci Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha